The Health Authority-Abu Dhabi (HAAD) and two top global research-driven pharmaceutical firms will today sign a memorandum of understanding (MoU) as part of efforts to combat cardiovascular diseases (CVD) and as part of the official launch of HAAD’s innovative forum.
The innovative forum, a collection of initiatives and partnerships with a broad range of academic, non-governmental organisations and private sector entities, will help curb the growing burden of chronic diseases in the emirate, Dr Oliver Harrison, director of Public Health and Policy, said during the HAAD launch on Monday.
The MoU, which seeks to help reduce the risk factors related to cardiovascular diseases, will be signed on Tuesday— during the final day of the World Health Care Congress Middle East (WHCC-ME).
It will be signed by HAA, Astra-Zeneca of the United Kingdom and Eli Lilly from of United States.
Dina El Shammaa
Gulf News